{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:22:28Z","timestamp":1756902148152,"version":"3.44.0"},"reference-count":14,"publisher":"The Pediatric Pharmacy Association","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>Acetaminophen (APAP) is an alternative to indomethacin and ibuprofen for treatment of patent ductus arteriosus (PDA). The side effect profile of non-steroidal anti-inflammatory drugs (NSAIDs) presents enteral feeding safety concerns; however, the safety of enteral feeding on APAP is largely unknown. Optimal feeding strategies during pharmacological PDA treatment are unknown, leading to practice variation. This study aims to assess the incidence of adverse gastrointestinal (GI) outcomes in neonates treated with APAP for PDA closure while receiving enteral feedings.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>Single-center retrospective cohort study of 59 extremely low birth weight (ELBW), premature neonates who received APAP for PDA treatment divided into Low Volume (LV; \u2264 20 mL\/kg\/day) and High Volume (HV; &amp;gt; 20 mL\/kg\/day) enteral feeding groups. The primary outcome was the incidence of any suspected or confirmed necrotizing enterocolitis (NEC). Timing of nutrition milestones, parenteral nutrition (PN) days, and adverse outcomes (feeding intolerance, liver dysfunction, death prior to discharge) were evaluated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>The incidence of suspected or confirmed NEC was 19.5% in the LV group and 13.3% in the HV group (p = 0.593). The HV group reached full feeds 6 days sooner (18 vs 24 days, p = 0.024) and had fewer PN days (17 vs 23.5 days, p = 0.044) with no difference in adverse outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Provision of &amp;gt; 20 mL\/kg\/day of enteral feeds during APAP treatment of PDA decreased time to full feeds and PN days compared to trophic feedings (\u2264 20 mL\/kg\/day) with no difference in adverse GI outcomes. Continuing enteral feeding during APAP PDA treatment appears safe while improving achievement of nutritional milestones.<\/jats:p>\n               <\/jats:sec>","DOI":"10.5863\/1551-6776-29.3.278","type":"journal-article","created":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T18:38:02Z","timestamp":1718044682000},"page":"278-285","source":"Crossref","is-referenced-by-count":0,"title":["Enteral Feedings Do Not Increase the Risk of NEC in ELBW Infants Undergoing Treatment of Patent Ductus Arteriosus With Acetaminophen"],"prefix":"10.5863","volume":"29","author":[{"given":"Katherine V.","family":"Katsivalis","sequence":"first","affiliation":[{"name":"Department of Pharmacy (KVK, JLJ, SH, KMW), Rush University Medical Center, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica L.","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Department of Pharmacy (KVK, JLJ, SH, KMW), Rush University Medical Center, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakhee","family":"Bowker","sequence":"additional","affiliation":[{"name":"Department of Pediatrics (RB, AB), Rush University Medical Center, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Berenz","sequence":"additional","affiliation":[{"name":"Department of Pediatrics (RB, AB), Rush University Medical Center, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Hovey","sequence":"additional","affiliation":[{"name":"Department of Pharmacy (KVK, JLJ, SH, KMW), Rush University Medical Center, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen W.","family":"Click","sequence":"additional","affiliation":[{"name":"Department of Pharmacy (KVK, JLJ, SH, KMW), Rush University Medical Center, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","published-online":{"date-parts":[[2024,6,10]]},"reference":[{"issue":"3","key":"2024061018373897800_i2331-348X-29-3-278-b01","first-page":"138","article-title":"Patent ductus arteriosus: an overview","volume":"12","author":"Dice","year":"2007","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2024061018373897800_i2331-348X-29-3-278-b02","doi-asserted-by":"crossref","first-page":"628317","DOI":"10.5402\/2012\/628317","article-title":"What really causes necrotising enterocolitis?","volume":"2012","author":"Fox","year":"2012","journal-title":"ISRN Gastroenterol"},{"issue":"2","key":"2024061018373897800_i2331-348X-29-3-278-b03","first-page":"184","article-title":"Patent ductus \u00adarteriosus, indomethacin and necrotizing enterocolitis in very low birth weight infants: a population-based study","volume":"40","author":"Dollberg","year":"2005","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"7","key":"2024061018373897800_i2331-348X-29-3-278-b04","doi-asserted-by":"crossref","first-page":"e394","DOI":"10.1542\/neo.19-7-e394","article-title":"Diagnosis and management of patent ductus arteriosus","volume":"19","author":"Gillam-Krakauer","year":"2018","journal-title":"Neoreviews"},{"issue":"10 Spec","key":"2024061018373897800_i2331-348X-29-3-278-b05","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1136\/adc.65.10_Spec_No.1067","article-title":"Gut blood flow velocities in the newborn: effects of patent ductus arteriosus and parenteral indomethacin","volume":"65","author":"Coombs","year":"1990","journal-title":"Archives Dis Childhood"},{"key":"2024061018373897800_i2331-348X-29-3-278-b06","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/1438038","article-title":"Paracetamol in patent ductus arteriosus treatment: efficacious and safe?","volume":"2017","author":"Bardanzellu","year":"2017","journal-title":"BioMed Res Internat"},{"issue":"6","key":"2024061018373897800_i2331-348X-29-3-278-b07","doi-asserted-by":"crossref","first-page":"e1618\u20131621","DOI":"10.1542\/peds.2011-0359","article-title":"Ductal closure with paracetamol: a surprising new approach to patent ductus arteriosus treatment","volume":"128","author":"Hammerman","year":"2011","journal-title":"Pediatrics"},{"key":"2024061018373897800_i2331-348X-29-3-278-b08","first-page":"CD010061","article-title":"Paracetamol (Acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants","volume":"4","author":"Ohlsson","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"2024061018373897800_i2331-348X-29-3-278-b09","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1055\/s-0034-1396687","article-title":"Nil-per-os days and necrotizing enterocolitis in extremely preterm Infants","volume":"32","author":"Kirtsman","year":"2015","journal-title":"Am J Perinatol"},{"issue":"1","key":"2024061018373897800_i2331-348X-29-3-278-b10","doi-asserted-by":"crossref","first-page":"E83","DOI":"10.3390\/nu12010083","article-title":"To feed or not to feed: a critical overview of enteral feedingmanagement and gastrointestinal ductus arteriosus","volume":"12","author":"Martini","year":"2019","journal-title":"Nutrients"},{"issue":"2","key":"2024061018373897800_i2331-348X-29-3-278-b11","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jpeds.2013.01.057","article-title":"Enteral feeding during indomethacin and ibuprofen treatment of a patent ductus arteriosus","volume":"163","author":"Clyman","year":"2013","journal-title":"J Pediatr"},{"issue":"7","key":"2024061018373897800_i2331-348X-29-3-278-b12","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/jp.2016.11","article-title":"Enteral feeding during indomethacin treatment for patent ductus arteriosus: association with gastrointestinal outcomes","volume":"36","author":"Louis","year":"2016","journal-title":"J Perinatol"},{"issue":"6","key":"2024061018373897800_i2331-348X-29-3-278-b13","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0022-3476(99)70093-4","article-title":"Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus","volume":"135","author":"Pezzati","year":"1999","journal-title":"J Pediatr"},{"issue":"3","key":"2024061018373897800_i2331-348X-29-3-278-b14","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMra1005408","article-title":"Necrotizing enterocolitis","volume":"364","author":"Neu","year":"2011","journal-title":"N Engl J Med"}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/29\/3\/278\/3385443\/i2331-348x-29-3-278.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/29\/3\/278\/3385443\/i2331-348x-29-3-278.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T18:41:57Z","timestamp":1738780917000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/29\/3\/article-p278.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,1]]},"references-count":14,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,6,10]]},"published-print":{"date-parts":[[2024,6,1]]}},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-29.3.278","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"type":"electronic","value":"2331-348X"},{"type":"print","value":"1551-6776"}],"subject":[],"published":{"date-parts":[[2024,6,1]]}}}